Duke Comp Cancer Ctr Core Support Grant

描述（由申请人提供）：杜克大学综合癌症中心（DCCC）负责并被授权作为杜克大学癌症活动的中心，并将这些活动的好处传递给我们的社区和社会。作为一个由美国国家癌症研究所（NCI）持续支持超过31年的矩阵中心，DCCC利用杜克大学的基础研究基础设施和卓越的临床肿瘤学研究，通过每年治疗4,800名新癌症患者，每年招募1,000多名患者进行治疗性临床试验，并通过国家肿瘤学研究资源的存在得到加强，例如两个NCI资助的合作小组的数据和统计中心。这些癌症研究活动得到了NCI 4800万美元的资助（比1998年增加了2700万美元）和近1.71亿美元的总研究资金（比1998年增加了6600万美元）的支持，并由DCCC和其他40个中心、SPORE和项目项目赠款以及合作协议进行协调。在这个竞争性更新申请中，我们要求支持358名成员（自1998年以来增加了68名）在17个共享资源支持的11个研究项目中工作。DCCC研究者已经取得了重大的基础科学进展，包括：DNA错配修复机制的理解，Ras结构md信号的作用，以及针对激素受体的新型抗癌药物的产生。这些进步与临床和人口研究相平衡，例如首次临床试验证明了一类新的抗癌化合物、抗血管生成剂和α发射器211-砹的益处；开发和示范使用脐带血作为移植用干细胞的来源；以及利用基因表达阵列谱来预测乳腺癌临床结果的发展和演示。DCCC受益于一项为期五年的筹款活动，该活动产生了1.13亿美元的慈善支持，创造了新的实验室和行政空间，启用了器官发生/干细胞生物学和成像的新开发项目，并增强了共享资源，如生物信息学，组织和血液采购，以及临床细胞处理。这项支持DCCC的申请阐明了推动DCCC充分利用生物医学研究的巨大进步来改善和延长癌症患者和癌症风险患者的生命的原则、目标和战略，并将这些成果交付给社会。

DESCRIPTION (provided by applicant): The Duke Comprehensive Cancer Center (DCCC) is charged and empowered to serve as the center of Duke activities in cancer and to deliver the benefits of these activities to our community and society. As a matrix center continuously supported by the National Cancer Institute (NCI) for over 31 years, the DCCC leverages Duke's basic research infrastructure with clinical oncology research excellence which is enabled by treating 4,800 new cancer patients annually, enrolling over 1,000 patients annually onto therapeutic clinical trials, and is enhanced by the presence of national oncology research resources, such as the data and statistical centers of two NCI-funded cooperative groups. These cancer research activities are supported by $48M in NCI funding (a $27 million increase from 1998) and nearly $171 million in total research funding (a $66 million increase from 1998) and are coordinate by the DCCC and forty other center, SPORE and program project grants as well as cooperative agreements. In this competitive renewal application, we request support for 358 members (an increase of 68 since 1998) working in 11 Research Programs supported by 17 Shared Resources. Significant basic scientific advances have been made by DCCC investigators including: an understanding of DNA mismatch repair mechanisms, the role of Ras structure md signaling, and the generation of novel anti-cancer agents targeting hormone receptors. These advances are balanced with clinical and population studies such as the first clinical trial demonstrating a benefit of a new class of anti-cancer compounds, the anti-angiogenesis agents and the alpha emitter 211-Astatine; the development and demonstration of the use of umbilical cord blood as a source of stem cells for transplantation; and the development and demonstration of the use of gene expression array profiling to predict clinical outcomes in breast cancer. The DCCC has benefited from a five-year fund raising campaign which generated $113 million in philanthropic support, generated new laboratory and administrative space, enabled new Programs-in-Development in Organogenesis/Stem Cell Biology and Imaging, and enabled enhancement of Shared Resources such as Bioinformatics, Tissue and Blood Procurement, and Clinical Cellular Processing. This application for support of the DCCC articulates the principles, goals and strategies for propelling the DCCC to fully leverage the enormous advances in biomedical research to improve and extend the lives of cancer patients with cancer and at risk for cancer, and delivering these to society.